drugset / Trial / NCT00865072

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions

NCT00865072

Phase 1 Completed 40 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

The purpose of this study is compare the relative bioavailability of 750 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co with that of 750 mg GLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 750 mg) in healthy adult volunteers under fasting conditions

Timeline

Start
2003-08
Primary completion
2003-08
Completion
2003-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 750 mg Oral

Indications

No indication recorded.